Trades on 1 secondary market

Agomab Therapeutics

Agomab Therapeutics is a clinical-stage biopharmaceutical company (Nasdaq: AGMB) developing novel disease-modifying therapies for fibro-inflammatory diseases, with an initial focus on chronic fibrotic indications of high unmet medical need such as Crohn's disease and idiopathic pulmonary fibrosis. B

minimal 11.9 / 100 0 APIs View provider profile →
CompanyBiopharmaceuticalBiotechnologyTherapeuticsFibrosisHealthcare

Agomab Therapeutics is an API provider whose private shares are listed on 1 secondary market: EquityZen.

Where It Trades

EZ EquityZen View listing →

Listing data is compiled from the public marketplace pages of Forge Global, Hiive, EquityZen, Nasdaq Private Market, and Augment. A listing indicates that a venue has published a page for this company — it is not an offer, a quote, or investment advice, and APIs.io has no affiliation with any venue.